In middle-aged diabetic subjects a two-fold to fourfold increased mortality compared with the general population has been reported [1] , with wide variations depending on the country [2] . Declining mortality risk with advancing age, and almost no excess mortality in those aged over 75 years, has also been suggested. Most mortality studies have, however, been hampered by great variation in diagnostic criteria and study design. In particular clinic-based cohorts are possibly not representative of the overall diabetic population, since diabetic patients attending hospital clinics are generally selected for severity of disease. In European countries few population-based studies are available [3±4].
Ó Springer- Verlag 1999 Summary The aims of this study were to assess the impact of diabetes and associated variables (fasting plasma glucose, blood pressure, antidiabetic treatment, body mass index) on general and cause-specific mortality in an Italian population-based cohort with Type II (non-insulin-dependent) diabetes mellitus, comprising mainly elderly patients. The patients (n = 1967) who had Type II diabetes were identified in 1988 with an 80 % estimated completeness of ascertainment. In 1995, a mortality follow-up (98 % completeness) of the cohort was done amounting to a total of 11 153 person-years. Observed and expected number of deaths were 577 and 428.7, respectively, giving a standardized mortality ratio (SMR) of 1.35 (95 % CI 1.24±1.46). The most common underlying causes of death were malignant neoplasm, ischaemic heart disease and cerebrovascular diseases, which accounted for 18 %, 17.8 % and 17.5 % of deaths, respectively. Cardiovascular disease as a whole (international classification of disease ICD-9 390±459) accounted for 260 of 577 deaths (SMR 1.21, 95 % CI 1.07±1.36). In internal analysis, the most important predictors of general mortality were insulin-treatment (relative risk [RR] 1.72, 95 % CI 1.19±2.49) and a fasting plasma glucose greater than 8.89 mmol/l ([RR] 1.29, 95 % CI 1.04±1.60), whereas the most important predictors of cardiovascular diseases were insulin-treatment and hypertension. In conclusion, this population-based study showed: 1) slight mortality excess of 35 % in Type II diabetes being associated with 2) a 30 % increased mortality in subjects with baseline fasting glucose greater than 8.89 mmol/l and 3) a 40 % increased risk of death from cardiovascular diseases in hypertensive patients. [Diabetologia (1999) . Completeness of ascertainment was estimated by using capture-recapture methods to be 80 % [7] . In all patients, the accuracy of previous diagnosis of diabetes mellitus was verified with the collaboration of general practitioners, using criteria defined by the National Diabetes Data Group (NDDG); patients were visited during their periodic appointment either at the diabetes clinic or at the general practitioner's office. At the baseline survey, the height and weight of the subjects (in indoor clothing without shoes) were measured with a beam balance and a stadiometer and BMI was calculated as body weight (Kg) divided by height (m 2 ) . Blood pressure was measured with a mercury sphygmomanometer in the patient's right arm with the patient in a sitting position. Hypertension was defined as systolic blood pressure 160 mm Hg or more or diastolic blood pressure 95 mm Hg or more or treatment with antihypertensive drugs. Information was collected on the date of first diagnosis of diabetes and on current treatment.
In 1995, a mortality follow-up of the cohort was carried out. Information as to which subjects had died was obtained from the demographical files of towns of their residence or death. As 26 patients were lost there was a 98.7 % completeness of follow-up. The underlying cause of death was derived and coded by two of the authors, according to the 9th revision of the International Classification of Disease (ICD) from that reported on the death certificate. The expected numbers of deaths were calculated by multiplying the number of person-years in each sex, 5-year age and calendar period for the mortality rates of the Italian population derived from the World Health Organisation (WHO) mortality database. The standardized mortality ratio (SMR) was defined as the ratio of observed to expected deaths. We calculated 95 % confidence intervals (CIs) of the SMR assuming a Poisson distribution of observed deaths. Relative risks of all causes of mortality were estimated by means of multivariate Poisson regression [8] . Sex, age (5-year groups), calendar period (10-year-groups), duration of diabetes (10-year-groups) and referring physician were included in the basic model. Also included in the model were antidiabetic treatment, hypertension, fasting plasma glucose (tertiles), BMI ( < 25; 25±29; 30 + kg/m 2 ) and smoking (never; former; current smoker).
Results
Mean ages ( standard deviation) at cohort identification and at diagnosis were 64 ± 10.6 years and 57.4 ± 11.3 years for men, and 68.4 ± 10.7 and 60.0 ± 11.6 years for women, respectively. Mean duration of diabetes was 8.5 ± 7.0 years. The prevalence of hypertension was 45.0 % for men and 51.5 % for women; 26 % of subjects were exclusively cared for by general practitioners. Mean fasting plasma glucose was 8.5 ± 2.6 mmol/l. Patients treated with diet, oral hypoglycaemic drugs and insulin (alone or combined with oral drugs) were 10.3 %, 76.2 %, 10.0 % and 3.5 %, respectively. The study cohort represents a total of 11 153 person-years of observation.
A total of 577 patients (249 men and 328 women) died between 1 October 1988 and 30 June 1995. Expected numbers of deaths were 428.7, giving an SMR of 1.35 (95 % CI 1.24±1.46). No differences between the sexes (Table 1 ) but a strong negative gradient of SMRs with increasing age was evident; 2.62 (95 % CI 1.83±3.62) at ages under 60 years, 1.86 (1.52±2.25) at ages 60±69 years, 1.37 (1.18±1.58) at ages 70±79 years and 1.12 (0.98±1.27) at ages over 80 years.
Cardiovascular disease as a whole (ICD-9 390±459) accounted for 260 of 577 deaths (SMR 1.21, 95 % CI 1.07±1.36). In both sexes, there were more deaths from ischaemic and cerebrovascular diseases but no increase in mortality from either malignant neoplasms or other causes of death was evident.
In internal analysis, no effect on mortality was found for duration of diabetes, referring physician, blood pressure and BMI. The most important predictors of general/cardiovascular diseases were insulintreatment and fasting plasma glucose greater than 8.89 mmol/l / insulin-treatment (association not statistically significant) and hypertension ( Table 2 ). The effect of glycaemic control on mortality was more pronounced though not significant for cerebrovascular diseases. Antidiabetic treatment was an important predictor of ischaemic heart disease, with an almost 3 times higher risk of death in subjects treated with insulin and 2.5 times higher risk in subjects treated with a combination of oral hypoglycaemic drugs. In contrast, no effect of antidiabetic treatment on risk of death from cerebrovascular diseases was found. The inclusion in the model of smoking did not modify relative risks of estimated variables. The results were essentially similar when the data were analysed separately for men and women.
We also analysed whether the predictive value of fasting plasma glucose with respect to all-cause and cause-specific mortality was modified by antidiabetic treatment, BMI, duration of disease or hypertension (Table 3) . Antidiabetic treatment and fasting plasma glucose were independently associated with all-cause mortality, with the highest RRs in insulin-treated subjects who had fasting plasma glucose concentrations 7.21 mmol/l or more. In contrast, in the highest tertile of fasting plasma glucose ( > 8.89 mmol/l), no effect of treatment was evident. No clear effect of BMI, duration of diabetes and blood pressure per se was observed. In fact, at all levels of these variables, the highest RR values were found in the highest tertile of fasting plasma glucose. This did not apply to obese subjects (BMI ³ 30 kg/m 2 ).
Discussion
In this Italian population-based cohort, patients with Type II diabetes showed only a 35 % increased mortality risk compared with non diabetic subjects. Most of the negative impact of the disease was, however, present in subjects in the younger age-group (2.6-fold increased risk in subjects < 60 years), which represented 27 % of the cohort. This finding, which was not confounded by duration of the disease, is relevant for public health planning, emphasising the need for prevention of the disease and its complications in the young.
Only two population-based mortality studies have been carried out on large European cohorts of patients diagnosed with diabetes according to National [3] . This figure is far apart from ours of 4 % patients with Type I diabetes and, even considering the 2±3 fold lower incidence of the disease in our area than in Scotland, indicates a likely overpresentation of Type I diabetic patients. The second population-based study was done in Verona in Italy and provided a similar result on all-cause mortality in Type II diabetes (SMR 1.44, 95 % CI 1.36±1.53) [4] . No attempt to assess the completeness of the cohort was described so that the extent of selection bias cannot be evaluated. Whether the fact that both available Italian studies provide a relatively low all-cause SMR is due to a specific favourable state of Italian diabetic patients, most of which are currently attending National Health Service diabetes clinics, remains to be assessed. Studies done on selected groups of patients who attend the diabetes clinic could be biased as general practitioners tend to selectively refer younger patients and those with poorer fasting plasma glucose to the diabetes clinic [6] . In our study, lost subjects were those who did not attend a diabetes clinic and a slightly lower prevalence of poor blood glucose control in these subjects is likely. Such bias in the referral causes a slight overestimation of SMRs. Thus, assuming that the mortality of the missing patients is only 75 % of that of those included, the overall SMR would decrease from 1.35 to 1.28 (95 % CI 1.19±1.38).
In our study baseline glycaemic control is related to all-cause mortality, with a 30 % higher risk in subjects with fasting plasma glucose over 8.89 mmol/l.
The increase in deaths from cardiovascular diseases is weaker (13 %), mainly due to cerebrovascular disease (47 %) and consistent with the hypothesis of worsening brain damage in the presence of higher glucose concentrations. Involvement of glycaemic control in atherosclerotic disease has been suggested by a Finnish study, showing a two-fold increased mortality in subjects aged 45±64 years with baseline fasting glucose in the highest tertile ( > 13.4 mmol/l) compared with those with values in the lower tertile ( < 9.6 mmol/l), together with an increase in cardiovascular morbidity in surviving subjects [9] . In our diabetic group, comprising mainly elderly subjects with only moderately impaired glucose tolerance, lower fasting glucose concentrations were found. Accordingly, the highest and the lowest tertiles of blood glucose distribution were defined by more than 8.89 mmol/l and less than 7.21 mmol/l, respectively. Our finding of increased mortality even in this span of fasting blood glucose distribution is remarkable, suggesting a negative impact of hyperglycaemia in a large proportion of the diabetic population. The few other studies examining the relation between hyperglycaemia and mortality risk have consistently found an association between these conditions [10±13]. Overall, they suggested that the association between cardiovascular diseases and glycaemia is weaker than that observed for the other risk factors [14] . In the Verona Study, instability of fasting plasma glucose rather than average value over 3 years was shown to predict all-cause and cardiovascular mortality in diabetic patients older than 75 years [15] . In that study, however, only patients attending the diabetes clinic were retrospectively evaluated, so that bias cannot be ruled out because macrovascular dis- eases impairing patients' autonomy could have reduced the clinic attendance, giving an underestimation of the effect. A higher risk of death from cardiovascular diseases, with 40 % increased risk for ischaemic heart disease, was found in hypertensive patients, confirming the negative impact of this condition in diabetic patients. The association of antidiabetic treatment with ischaemic heart disease mortality is of note, indicating a 2.5-fold increase in risk of death in patients treated with both sulphonylurea drugs and biguanides and a 3-fold increase in those treated with insulin. No effect of antidiabetic treatment was observed on cerebrovascular diseases. Our results though should be interpreted with caution because of the relatively small numbers of events.
No evidence was found of an association between mortality and BMI which is consistent with the WHO Multinational Study of Vascular Disease in Diabetes [16] .
In conclusion, this population-based study showed: 1) a slight overall excess of mortality (35 %) in Type II diabetes; 2) a 30 % increased mortality in patients with baseline fasting glucose over 8.89 mmol/l and 3) a 40 % increased risk of death from cardiovascular diseases in hypertensive diabetic patients.
